Organization | Government of India

Government of India Report issue

Government Phase 2 Phase 3 Phase 4

Founded: New Delhi India (1947)

Organization Overview

First Clinical Trial

1997

NCT00123669

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

All India Institute of Ayurveda, Ministry of AYUSH, Government of India | Armed Forces Institute of Urology. | Bhabha Atomic Research Centre (BARC), Mumbai | Centre for Chronic Disease Control | Centre for Chronic Disease Control (CCDC) | Centre for Chronic Disease Control, India | Coconut Development Board, Government of India | Department of Science and Technology, Government of India | Directorate of Public Health and Preventive Medicine,Chennai | ICMR-National Institute of Cholera and Enteric Diseases,West Bengal | Indian Institute of Public Health, India | Kilkari , Lucknow , India | Ministry of Health & Family Welfare, India | Ministry of Science and Technology, India | National Institute for Research in Environmental Health, Bhopal, Madhya Pradesh | National Institute of Nutrition, India | National Institute of Occupational Health | National Institute of Occupational Health, Ahmedabad, Gujarat | New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India

Active Ingredients

Drugs in Phase 4 Trials (14)

acetaminophen (tylenol) (1 trial)

amlodipine (norvasc) (1 trial)

atorvastatin (lipitor) (1 trial)

bupivacaine (Exparel) (1 trial)

coconut oil (1 trial)

dimenhydrinate (1 trial)

human rotavirus, live attenuated (Rotarix) (4 trials)

indapamide (lozol) (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus rhamnosus (1 trial)

orphenadrine hydrochloride (disipal) (1 trial)

perindopril (aceon) (1 trial)

polio, inactivated poliovirus vaccine (Salk Vaccine) (1 trial)

zinc (2 trials)

Drugs in Phase 3 Trials (22)

acetylsalicylic acid (aspirin) (1 trial)

arsenic trioxide (trisenox) (1 trial)

atenolol (tenormin) (1 trial)

bacille calmette-guerin (1 trial)

cpl-2009-0031 (1 trial)

ethambutol (myambutol) (2 trials)

fish oil (Omegavan) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

hydroxyprogesterone (Delalutin) (1 trial)

icosapent ethyl (vascepa) (1 trial)

imidazoquinoline (1 trial)

isoniazid (nydrazid) (2 trials)

lactose (1 trial)

lisinopril (zestril) (1 trial)

moxifloxacin (avelox) (1 trial)

mycobacterium w vaccine (2 trials)

pyrazinamide (Aldinamide) (2 trials)

rifampin (2 trials)

simvastatin (zocor) (1 trial)

sitagliptin (januvia) (1 trial)

vitamin d3 (1 trial)

zinc dichloride (1 trial)

Drugs in Phase 2 Trials (4)

allogeneic adipose derived mesenchymal stem cell (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

fetal liver-derived mesenchymal stem cells (1 trial)

sodium copper chlorophyllin (1 trial)

Drugs in Other Trials (4)

piper longum (1 trial)

tinospora (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

Breast Neoplasms (Phase 3)

Cardiovascular Diseases (Phase 3)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Coronavirus Infections (Phase 3)

Diarrhea (Phase 2)

Dyslipidemias (Phase 4)

Gastroenteritis (Phase 3)

HIV Infections (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Promyelocytic, Acute (Phase 3)

Osteogenesis Imperfecta (Phase 2)

Poliomyelitis (Phase 4)

Rotavirus Infections (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Stroke (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Ulcer (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 30
# of Trial APIs: 44